TABLE 6

Risk of hypersensitivity pneumonitis combining home visit and interview data

Risk factorOR (95% CI)p-value
Model 1. All home visits participants: cases (n=118) and referents (n=106)
 FEV1% and FVC% both <80% predicted2.66 (1.25–5.62)0.0107
 Exhaled NO ppb1.03 (1.00–1.07)0.0249
 Alveolar NO ppb1.02 (0.95–1.10)0.5368
 Elevated serum avian antibody0.90 (0.17–4.69)0.8959
 Elevated serum mould precipitins2.03 (0.59–6.90)0.2576
 HSCRP >90th percentile1.69 (0.44–3.13)0.7539
 CC16 >90th percentile3.07 (1.21–7.83)0.0184
 sST2 >90th percentile1.67 (0.70–3.95)0.2465
 Any occupational exposure2.83 (1.44–5.53)0.0024
 Bird (nonoccupational)2.78 (1.08–7.17)0.0341
 Mould (nonoccupational)1.43 (0.70–2.93)0.3214
Model 2. IHCDS cases (n=83) cases and referents (n=106)
 FEV1% and FVC% both <80% predicted2.43 (1.08–5.47)0.0320
 Exhaled NO ppb1.03 (1.00–1.06)0.0510
 Alveolar NO ppb1.02 (0.95–1.09)0.6631
 Elevated serum mould precipitins1.54 (0.37–6.36)0.5499
 Elevated serum avian antibody1.00 (0.18–5.38)0.9966
 HSCRP >90th percentile1.14 (0.39–3.31)0.8051
 CC16 >90th percentile2.91 (1.03–8.26)0.0440
 sST2 >90th percentile1.14 (0.43–3.02)0.7907
 Any occupational exposure3.53 (1.72–7.23)0.0006
 Bird (nonoccupational)2.81 (1.09–7.27)0.0326
 Mould (nonoccupational)0.96 (0.42–2.18)0.9199
Model 3. UCSF cases (n=35) and IHCDS controls (n=106)
 FEV1% and FVC% both <80% predicted3.67 (1.15–11.74)0.0284
 Exhaled NO ppb1.04 (0.99–1.09)0.0846
 Alveolar NO ppb1.06 (0.99–1.17)0.1921
 Elevated serum avian antibody0.65 (0.04–9.59)0.7518
 Elevated serum mould precipitins3.97 (0.87–17.82)0.0754
 HSCRP >90th percentile1.07 (0.25–4.58)0.9923
 CC16 >90th percentile4.26 (1.27–16.11)0.0327
 sST2 >90th percentile3.86 (1.11–13.43)0.0343
 Any occupational exposure1.13 (0.37–3.42)0.8336
 Bird (nonoccupational)1.78 (0.35–9.13)0.4876
 Mould (nonoccupational)3.69 (1.25–10.93)0.0184

FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; NO: nitric oxide; HSCRP: high-sensitivity C-reactive protein; CC16: club cell secretory protein; sST2: soluble suppression of tumorigenicity 2; IHCDS: Integrated Health Care Delivery System; UCSF: University of California San Francisco.